REG - Ondine Biomedical - First German Hospital Pilots Steriwave

Ondine BiomedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251222:nRSV3735Ma&default-theme=true

RNS Number : 3735M  Ondine Biomedical Inc.  22 December 2025

22 December 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

First German Hospital Pilots Steriwave

 

Ondine Biomedical Partners with LMU University Hospital Munich

 to Trial Steriwave in ENT Patients

 

 

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce a significant
research collaboration with LMU University Hospital Munich, one of Europe's
most esteemed and highly ranked medical institutions. This partnership marks a
pivotal step in introducing Ondine's Steriwave® photodisinfection technology
to Germany, the European Union, and other major international markets,
underscoring the growing importance of innovative infection prevention
solutions in global healthcare.

 

The collaborative research initiative will be led by Professor Dr. Ronald
Sroka, Head of the LIFE Center and Laser Research Laboratory at LMU University
Hospital Munich, along with PD Dr. Veronika Volgger, Clinical Scientist at
LIFE Center and Department of ENT at LMU University Hospital Munich. Renowned
for its excellence in biophotonics and photodynamic therapy (PDT), the LIFE
Center brings unparalleled expertise to this project, further strengthening
the scientific foundation for Steriwave's clinical evaluation in ENT patients.

 

This initiative is bolstered by external clinical evidence, including a pilot
study presented at the American Rhinologic Society's 66th Annual Meeting in
2020 by Prof. Claire Hopkins, consultant ENT surgeon at Guy's & St Thomas
Hospital and London Bridge Hospital, and her team. Their findings demonstrated
that routine pre-operative nasal photodisinfection significantly reduced the
need for post-operative antibiotics in sinonasal surgery patients, with
prescription rates dropping from 22.5% to 5% (P=0.02), highlighting the
technology's potential to combat healthcare-associated infections and
antimicrobial resistance.

 

Professor Dr. Ronald Sroka commented:

"Innovative solutions are more vital than ever in the fight against antibiotic
resistance. Our team at LMU is deeply committed to advancing photodynamic
approaches that address the growing threat of antimicrobial resistance.
Ondine's Steriwave represents a promising, non-antibiotic strategy to reduce
multidrug-resistant infections, and we are delighted to bring our clinical
expertise to validate this important technology and help reduce unnecessary
post-surgical infections."

 

Carolyn Cross, CEO of Ondine Biomedical Inc., stated:

"We are truly honoured to partner with the outstanding and visionary team at
LMU University Hospital Munich. Their leadership in photodynamic therapy and
commitment to scientific excellence make them the ideal collaborators as we
introduce our innovative photodisinfection technology to Germany, the EU, and
key global markets. This collaboration reflects our shared dedication to
combating antibiotic resistance and delivering safe, effective infection
prevention solutions that can transform patient care and outcomes worldwide."

 

About the LMU Hospital

The LMU University Hospital Munich (LMU Klinikum) is a leading institution in
European medicine. In conjunction with the medical faculty of the esteemed
Ludwig-Maximilians-Universität München, it constitutes one of the largest
university hospitals in Germany and maintains significant influence throughout
Europe. Regularly ranked among the Top 3-4 hospitals in Germany and within the
Top 30 globally by Newsweek/Statista, LMU Klinikum delivers exemplary patient
care, serving more than 500,000 patients each year across its two principal
campuses.

 

About Steriwave(®) Nasal Photodisinfection

Steriwave is CE-marked for nasal decolonisation. The treatment involves
applying the proprietary Steriwave photosensitive agent to each nostril
followed by illumination with a specific wavelength of red light. When used
per the instructions for use, evidence demonstrates rapid reduction of nasal
pathogens.

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

 

 

Enquiries:

 

 Ondine Biomedical Inc.                                            www.ondinebio.com
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

 

 

FOR INVESTOR AND MEDIA INFORMATION ONLY; NOT FOR PATIENT USE OR PROMOTIONAL
PURPOSES.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKFLBLELLZFBE



            Copyright 2019 Regulatory News Service, all rights reserved